Search Results - "Pang, Phil"

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older by Saab, Sammy, Park, Sarah H., Mizokami, Masashi, Omata, Masao, Mangia, Alessandra, Eggleton, Ed, Zhu, Yanni, Knox, Steven J., Pang, Phil, Subramanian, Mani, Kowdley, Kris, Afdhal, Nezam H.

“…Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to…”
Get full text

All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection by Wyles, David L., Rodriguez‐Torres, Maribel, Lawitz, Eric, Shiffman, Mitchell L., Pol, Stanislas, Herring, Robert W., Massetto, Benedetta, Kanwar, Bittoo, Trenkle, James D., Pang, Phil S., Zhu, Yanni, Mo, Hongmei, Brainard, Diana M., Subramanian, G. Mani, McHutchison, John G., Habersetzer, François, Sulkowski, Mark S.

“…This phase II trial assessed the efficacy and safety of a combination regimen of the nonstructural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease…”
Get full text

SAT424 - Impact of ESC+ technology on the hepatic safety profile of GalNAc-delivered, HBV-targeting RNAi therapeutics by Gane, Edward, Schwabe, Christian, Taubel, Jorg, Bakardjiev, Anna, Huang, Stephen, Ding, Xiao, Connolly, Lynn, Pang, Phil, Garg, Pushkal, Jadhav, Vasant

Get full text

Impact of ESC+ technology on the hepatic safety profile of GalNAc-delivered, HBV-targeting RNAi therapeutics by Gane, Edward, Schwabe, Christian, Taubel, Jorg, Bakardjiev, Anna, Huang, Stephen, Ding, Xiao, Connolly, Lynn, Pang, Phil, Garg, Pushkal, Jadhav, Vasant

Get full text

Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients by Gane, Edward, Lim, Young-Suk, Tangkijvanich, Pisit, O’Beirne, James, Lim, Tien Huey, Bakardjiev, Anna, Ding, Xiao, Connolly, Lynn, Huang, Stephen, Kim, Jae, Pang, Phil, Yuen, Man-Fung

Get full text

AS068 - Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients by Gane, Edward, Lim, Young-Suk, Tangkijvanich, Pisit, O’Beirne, James, Lim, Tien Huey, Bakardjiev, Anna, Ding, Xiao, Connolly, Lynn, Huang, Stephen, Kim, Jae, Pang, Phil, Yuen, Man-Fung

Get full text

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank by Narayanasamy, Shanti, Curtis, Lesley H, Hernandez, Adrian F, Woods, Christopher W, Moody, M Anthony, Sulkowski, Mark, Turbett, Sarah E, Baden, Lindsey R, Gulick, Roy M, Pau, Alice K, Adam, Stacey J, Marks, Peter, Stockbridge, Norman L, Dobbins, John R, Krofah, Esther, Leav, Brett, Pang, Phil, Roessig, Lothar, Vedin, Ola, Waldstreicher, Joanne, Berman, Stacey Cromer, Cremisi, Henry, Schofield, Lesley, Gandhi, Rajesh T, Naggie, Susanna

“…Abstract While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons…”
Get full text

Virologic Response Rates to Fixed-Dose Combination Ledipasvir/Sofosbuvir for 8 or 12 Weeks With Baseline Viral Load: 2061 by Hawkins, Trevor, Arora, Sanjeev, Everson, Greg, Freilich, Bradley, Kugelmas, Marcelo, Gordon, Stuart, Llewellyn, Joe, Hammond, Kyle, Seyedkazemi, Star, Natha, Macky, Pang, Phil

Get full text

Ledipasvir/Sofosbuvir With or Without Ribavirin for the Treatment of Patients With Genotype 2-6 Chronic HCV Infection: Summary Results From Four Phase II Studies: 2071 by Gane, Edward, Stedman, Catherine A. M., Asselah, Tarik, Kohli, Anita, Mir, Heshaam M., Natha, Macky, Kersey, Kathryn, Hyland, Robert H., Pang, Phil, McHutchison, John G., Abergel, Armand

Get full text

238 Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in HCV Infected Populations Including Decompensated Patients and Patients With Prior Sofosbuvir Treatment Experience by Gane, Edward, Hyland, Rob H, Pang, Phil, Symonds, William T, McHutchison, John G, Stedman, Catherine A

Get full text

365 Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial by Gane, Edward, Manns, Michael P, Forns, Xavier, Samuel, Didier, Charlton, Michael R, Denning, Jill, Arterburn, Sarah, Brandt-Sarif, Theo S, Pang, Phil, McHutchison, John G, Mutimer, David

Get full text

Tu1016 Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 by Saab, Sammy, Mizokami, Masashi, Omata, Masao, Mangia, Alessandra, Eggleton, Ed, Seyedkazemi, Star, Zhu, Yanni, Knox, Steven J, Pang, Phil, Subramanian, G.M, Kowdley, Kris, Afdhal, Nezam H

Get full text

Tu1018 Sofosbuvir-Based Regimens for Patients With Hepatitis C Virus Genotype 3 Infection: Summary Results From the VALENCE, LONESTAR-2, and ELECTRON-2 Studies by Lawitz, Eric, Zeuzem, Stefan, Stedman, Catherine A, Poordad, Fred, Mir, Heshaam M, Seyedkazemi, Star, Hyland, Robert H, Pang, Phil, Brainard, Diana M, McHutchison, John G, Gane, Edward

Get full text

226 Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the Solar 1 and Solar 2 Trials by Charlton, Michael R, Samuel, Didier, Manns, Michael P, Forns, Xavier, Flamm, Steven L, Reddy, K. Rajender, Denning, Jill, Arterburn, Sarah, Brandt-Sarif, Theo S, Pang, Phil, McHutchison, John G, Afdhal, Nezam H, Gane, Edward, Mutimer, David, Everson, Gregory T

Get full text

Tu1021 Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation by Everson, Gregory T, Forns, Xavier, Mutimer, David, Manns, Michael P, Reddy, K. Rajender, Flamm, Steven L, Denning, Jill, Arterburn, Sarah, Brandt-Sarif, Theo S, Pang, Phil, McHutchison, John G, Afdhal, Nezam H, Charlton, Michael R, Samuel, Didier, Gane, Edward

Get full text

364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin by Reddy, K. Rajender, Sarrazin, Christoph, Sulkowski, Mark, Omata, Masao, Zeuzem, Stefan, Feld, Jordan J, Lawitz, Eric, Hyland, Robert H, Ding, Xiao, Yang, Jenny C, Dvory-Sobol, Hadas, Knox, Steven J, Pang, Phil, Subramanian, G.M, McHutchison, John G, Mangia, Alessandra, Gane, Edward, Mizokami, Masashi, Afdhal, Nezam H, Bourliere, Marc

Get full text

236 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCVInfected Patients: The Phase 3 Ion-2 Study by Kwo, Paul Y, Reddy, K. Rajender, Pockros, Paul J, Di Bisceglie, Adrian M, Arora, Sanjeev, Yang, Jenny C, Dvory-Sobol, Hadas, Zhu, Yanni, Pang, Phil, Symonds, William T, McHutchison, John G, Sulkowski, Mark, Afdhal, Nezam H

Get full text

764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study by Kowdley, Kris V, Gordon, Stuart C, Reddy, K. Rajender, Rossaro, Lorenzo, Bernstein, David, An, Di, Svarovskaia, Evguenia, Hyland, Rob H, Pang, Phil, Symonds, William T, McHutchison, John G, Muir, Andrew J, Pockros, Paul J, Pound, David, Fried, Michael W

Get full text

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study by Jacobson, Ira M, Marcellin, Patrick, Mangia, Alessandra, Kwo, Paul Y, Foster, Graham, Buti, Maria, Brau, Norbert, Muir, Andrew J, Yang, Jenny C, Mo, Hongmei, Ding, Xiao, Pang, Phil, Symonds, William T, McHutchison, John G, Zeuzem, Stefan, Afdhal, Nezam H

Get full text

Factors Associated with More Severe BK Hemorrhagic Cystitis in an Allogeneic Hematopoietic Cell Transplant Cohort by Imlay, Hannah, Xie, Hu, Leisenring, Wendy M, Kimball, Louise, Pang, Phil S, Pergam, Steven A., Limaye, Ajit, Boeckh, Michael J

“…BK polyoma virus (BKPyV) has been associated with hemorrhagic cystitis (HC) after hematopoietic cell transplant (HCT). Prior studies have examined risk factors…”
Get full text